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Abstract
Objective—To determine whether dobut-
amine stress echocardiography can pre-
dict the improvement of left ventricular
systolic function in patients with dilated
cardiomyopathy (DCM).
Methods—Myocardial contractile reserve,
as assessed by dobutamine stress echo-
cardiography, was determined in 18 pa-
tients with DCM (mean (SD) age 53 (13)
years, left ventricular ejection fraction
(LVEF) 28 (10)%) and compared with
changes in LVEF during a follow up period
of 15 (8) months. The LVEF and regional
left ventricular wall motion score (0,
normal to 4, dyskinesis) of 12 segments in
short axis and four chamber views were
analysed before and after dobutamine
infusion (5–20 µg/kg/min).
Results—During a follow up period of 15
(8) months, a significant improvement in
LVEF (> 20%) was found in seven patients
but not in the remaining 11. Baseline
haemodynamic findings were similar in
both groups. Patients with an improve-
ment in follow up LVEF showed a greater
change in wall motion score from baseline
during dobutamine infusion than patients
with no improvement (at rest, 1.7 (0.4) v
1.9 (0.2), NS; dobutamine 10 µg/kg/min,
0.6 (0.4) v 1.2 (0.4), p < 0.05). The per-
centage change in LVEF during dobut-
amine infusion was also significantly
greater in patients who showed improve-
ment than in those who did not. The
change in LVEF during the follow up
period (follow up LVEF/baseline LVEF)
correlated well with the change in LVEF
during dobutamine stress (LVEF at rest/
LVEF at dobutamine 10 µg/kg/min;
r = 0.74, p < 0.001).
Conclusions—Changes in left ventricular
systolic performance during low dose
dobutamine stress echocardiography are
a useful marker to predict the outcome of
left ventricular systolic function in pa-
tients with DCM.
(Heart 1999;81:523–527)
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Idiopathic dilated cardiomyopathy (DCM) has
a poor prognosis, although treatment with
vasodilators, angiotensin converting enzyme
(ACE) inhibitors, and â blockers has been
shown to improve the prognosis in patients
with heart failure.1–3 On the other hand, it is
reported that some patients with DCM experi-
ence an improvement in left ventricular systolic
function.4–7 Although in such patients predic-
tion of improvement is important in consider-
ing eligibility for heart transplantation, it has
been reported that there are no significant dif-
ferences in the clinical characteristics deter-
mined at initial examination—except in rela-
tion to myocardial fibrosis observed in
endomyocardial biopsies and alcohol
consumption—between patients showing im-
provement and those who do not.8–10
Dobutamine stress echocardiography has
been widely used in assessing the myocardial
viability and prognosis in patients with ischae-
mic left ventricular dysfunction.11 12 However,
its value in patients with non-ischaemic left
ventricular dysfunction is not clear. Our
purpose in this study was to clarify whether
dobutamine stress echocardiography can pre-
dict the improvement of left ventricular systolic
function in patients with DCM.
Methods
SUBJECTS
We studied 18 patients with DCM. A careful
history was taken from all the patients, and
they were given a physical examination, blood
test, chest x ray, standard electrocardiography,
exercise stress test, dipyridamole stress, 201Tl
scintigraphy, and cardiac catheterisation, in-
cluding coronary angiography and biplane left
ventriculography. Patients with acute myocar-
ditis, significant coronary artery stenosis,
valvar disease, or a left ventricular end diastolic
volume below 85 ml/m2 were excluded. All
patients were initially treated with ACE inhibi-
tors, diuretics, and digitalis. Seven patients
were also treated with â blockers.
DOBUTAMINE STRESS ECHOCARDIOGRAPHY
After baseline electrocardiography and echo-
cardiography had been recorded, dobutamine
was infused intravenously, beginning at 5
µg/kg/min and increasing to 10 and 20
µg/kg/min at five minute intervals, with con-
tinuous electrocardiography and blood press-
ure monitoring.
The left ventricular end diastolic dimensions
and end systolic dimensions were measured in
the parasternal longitudinal position. The left
ventricular ejection fraction (LVEF) was calcu-
lated according to a previously reported
method.13 The left ventricle was divided into 12
segments (six in the short axis view and six in
the four chamber view). The wall motion score
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(0, normal; 1, mild hypokinesis; 2, severe hypo-
kinesis; 3, akinesis; 4, dyskinesis) was obtained
for each segment at rest and at a dobutamine
dose of 5, 10, and 20 µg/kg/min. The wall
motion score index (WMSI), defined as the
sum of the wall motion scores divided by the
number of segments, was also analysed.
THALLIUM-201 MYOCARDIAL SCINTIGRAPHY
201Tl SPECT was performed in 17 patients.
The left ventricular myocardium was divided
into 13 segments using basal and mid-short
axis slices and an apical slice. 201Tl uptake was
then scored in each segment using a grading
scale (3, normal; 2, mildly reduced; 1, moder-
ately reduced; 0, severely reduced).
CARDIOPULMONARY EXERCISE TEST
Symptom limited cardiopulmonary exercise
testing was performed in 15 patients on an
upright bicycle ergometer. Exercise workload
was increased by the ramp incremental proto-
col of 15 W/min after pedalling against zero
resistance for one minute. All patients stopped
exercise on presentation of dyspnoea or leg
fatigue—that is, above 18 on the Borg scale.
The electrocardiographic findings and blood
pressure measured by sphygmomanometer
were recorded at rest, at every minute during
exercise, and for five minutes after exercise.
The expired gas was measured on a breath
by breath basis during the test with a respiro-
monitor AE280 (Minato Medical Electronics,
Osaka, Japan) connected to a personal compu-
ter equipped with analysing software.
FOLLOW UP
The mean (SD) follow up period was 15 (8)
months. Follow up echocardiography and
clinical outcome was obtained in all patients. A
significant improvement of LVEF (greater than
20%) was found in seven patients (group A);
however, no such improvement occurred in the
remaining 11 patients (group B).
STATISTICAL ANALYSIS
Results are expressed as mean (SD). Unpaired
t and ÷2 tests were used for comparison of the
two groups. Linear regression analysis was used
to evaluate the correlation between the re-
sponse of the left ventricle to dobutamine and
Table 1 Baseline, echocardiographic, and haemodynamic
characteristics
Group A
(n = 7)
Group B
(n = 11) p Value
Clinical findings
Age (years) 49 (13) 55 (15) NS
Range (23 to 60) (23 to 70)
Male/female 5/2 10/1
NYHA class (II/III) 6/1 8/3 NS
â Blocker use 4 3 NS
Alcohol intake (> 100 g/day) 3 4 NS
Echocardiographic findings
LVEDD (mm) 59 (9) 65 (7) NS
LVESD (mm) 52 (9) 56 (8) NS
Haemodynamic findings
LVEF (%) 35 (8) 33 (9) NS
LVEDVI (ml/m2) 154 (48) 157 (49) NS
LVESVI (ml/m2) 95 (30) 105 (40) NS
LVEDP (mm Hg) 9 (3) 16 (10) NS
PCW (mm Hg) 8 (2) 12 (9) NS
PA mean (mm Hg) 20 (5) 22 (9) NS
RVEDP (mm Hg) 7 (2) 9 (5) NS
RA mean (mm Hg) 5 (2) 6 (4) NS
Cardiac index (l/min/m2) 2.7 (0.7) 2.2 (0.5) NS
Values are n or mean (SD).
LVEDD, left ventricular end diastolic dimension; LVEDVI, left
ventricular end diastolic volume index; LVEF, left ventricular
ejection fraction; LVEDP, left ventricular end diastolic pressure;
LVESD, left ventricular end systolic dimension; LVESVI, left
ventricular end systolic volume index; NYHA, New York Heart
Association; PA, pulmonary artery; PCW, pulmonary capillary
wedge pressure; RA, right atrium; RVEDP, right ventricular end
diastolic pressure.
Table 2 Cardiovascular response to dobutamine
Group A Group B p Value
Rest
HR (beats/min) 88 (15) 72 (15) NS
Systolic BP (mm Hg) 120 (16) 122 (16) NS
LVEF (%) 27 (9) 29 (11) NS
5 µg/kg/min*
HR 92 (13) 76 (15) NS
Systolic BP 138 (25) 131 (17) NS
LVEF 43 (10) 39 (12) NS
10 µg/kg/min*
HR 106 (18) 84 (16) < 0.05
Systolic BP 147 (29) 142 (21) NS
LVEF 52 (13) 41 (15) NS
20 µg/kg/min*
HR 130 (32) 109 (22) NS
Systolic BP 142 (30) 147 (22) NS
LVEF 51 (9) 44 (16) NS
Values are mean (SD).
*Dobutamine dose.
BP, blood pressure; HR, heart rate; LVEF, left ventricular ejec-
tion fraction.
Figure 1 Serial change in mean wall motion score index
(WMSI) during dobutamine stress echocardiography. A
greater improvement of wall motion was observed in group
A than in group B. *p < 0.05.
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Figure 2 Change in LVEF (LVEF during dobutamine
infusion − LVEF at rest/LVEF at rest). This was
significantly greater in group A at the dobutamine infusion
dose of 10 mg/kg/min. *p < 0.05.
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the improvement of left ventricular systolic
function during the follow up period. A p value
of < 0.05 was considered statistically signifi-
cant.
Results
BASELINE CHARACTERISTICS AND CLINICAL
OUTCOME
Baseline, echocardiographic, and haemody-
namic characteristics are shown in table 1.
There were no significant diVerences in
baseline and haemodynamic characteristics
between the two groups, although group A
tended to have somewhat lower baseline left
ventricular end diastolic pressure and pulmo-
nary capillary wedge pressure, and higher car-
diac index compared with group B. The mean
201Tl uptake score in 13 segments was similar
between the two groups (group A, 2.1 (0.5) v
group B, 2.3 (0.3), NS). A large perfusion
defect exceeding one segment was found in one
patient in group A and in two patients in group
B. Peak oxygen consumption in cardiopulmon-
ary exercise testing was also not significantly
diVerent between the two groups (group A,
18.5 (5.3) ml/min/kg v group B, 18.2 (3.6)
ml/min/kg), although heart rate at rest and at
low level exercise in group A was higher than in
group B (rest, 88.7 (9.6) v 78.9 (11.3)
beats/min; 45 W, 110.5 (10.9) v 100.7 (8.4)
beats/min; 60 W, 116.5 (6.5) v 108.3 (9.6)
beats/min, NS). One patient in group A and
three patients in group B experienced conges-
tive heart failure during the follow up period.
DOBUTAMINE STRESS ECHOCARDIOGRAPHY
Cardiovascular response to dobutamine infusion
No patients complained of chest pain or
dyspnoea, neither were ventricular tachycardia
and hypotension observed in any patient. Heart
rate and blood pressure responses during dobut-
amine infusion are shown in table 2. There
were no significant diVerences between the two
groups except that heart rate at the dobutamine
infusion rate of 10 µg/kg/min was faster in
group A.
Wall motion score index
WMSI values are shown in fig 1. The WMSI at
rest was 1.7 (0.4) in group A and 1.9 (0.5) in
group B (NS). After dobutamine stress, the
WMSI in group A became significantly smaller
than in group B both at 10 µg/kg/min (0.6 (0.4)
v 1.2 (0.7), p < 0.05) and at 20 µg/kg/min
(0.30 (0.3) v 1.1 (0.7), p < 0.05), although it
gradually improved in both groups (fig 1).
Thus the change in WMSI in group A was
greater than in group B. With a cut oV value of
WMSI set at 1.0 at 10 µg/kg/min, sensitivity
and specificity in predicting future improve-
ment of LVEF were 85% and 81%, respec-
tively. Positive predictive value was 75%.
Left ventricular ejection fraction
Changes in LVEF are shown in table 2 and fig
2. The LVEF tended to increase during
dobutamine infusion in both groups. A greater
mean increase in LVEF in group A than in
group B was not statistically significant (table
2). Figure 2 shows the percent change in LVEF
(LVEF at each dobutamine dose minus LVEF
at rest divided by LVEF at rest). The percent-
age change in LVEF in group A was signifi-
cantly greater than in group B at the dob-
utamine infusion rate of 10 µg/kg/min (98
(33)% v 45 (33)%, p < 0.005).
RESPONSE OF LVEF TO DOBUTAMINE AND
FOLLOW UP IMPROVEMENT
The LVEF values at the initial examination and
at the last follow up are shown in fig 3. By defi-
nition in this study, a significant improvement
in LVEF was observed in group A (27 (9)% →
56 (8)%, p < 0.0001), whereas minimal
change was seen in group B (29 (11)% → 34
(11)%, p < 0.005).
We examined the correlation between the
response of LVEF to dobutamine and follow
up improvement (LVEF at follow up/LVEF at
baseline). As shown in fig 4, the response of
Figure 3 LVEF at the initial examination and at the last follow up in the two groups.
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Figure 4 Correlation between the response of LVEF to dobutamine and the improvement of LVEF during the follow up
period. A good correlation was shown at dobutamine infusion doses of both 10 µg/kg/min and 20 µg/kg/min.
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LVEF both at 10 and 20 µg/kg/min was well
correlated with follow up LVEF improvement.
Discussion
In this study, a significant improvement of left
ventricular systolic function was seen in seven
(39%) of 18 patients with DCM, and this
improvement correlated well with the response
of left ventricular function during the dobut-
amine stress echocardiography at baseline.
NATURAL HISTORY OF DCM
Idiopathic DCM—characterised by dilated
ventricles and decreased systolic function—has
usually been regarded as having a poor
prognosis. In early reports, survival was 70–
75% at one year and 50% at five years.4 14
However, in recent reports the prognosis has
been better, with a five year survival rate of
65–80%.15 16 Earlier detection of the disease as
well as newer treatments with ACE inhibitors
and â blockers may be related to this improve-
ment in prognosis.
On the other hand, a marked improvement
in left ventricular systolic function has been
reported in 20–45% of patients with DCM.5 7 8
In this study, an improvement in left ventricu-
lar function was observed in 39% of the
patients. In line with previous findings, this
relatively high percentage of patients with
improvement may well be related to our earlier
use of ACE inhibitors and â blockers. It is also
possible that there were some patients with
myocarditis in our study, since changes in ven-
tricular size and function are common in these
patients; however, we did our best to exclude
patients with a possible history of myocarditis.
Nonetheless, to be able to predict such
improvements non-invasively is of clinical
importance in patients with non-ischaemic left
ventricular dysfunction, particularly in relation
to indications for heart transplantation.
FACTORS INFLUENCING THE IMPROVEMENT OF
LEFT VENTRICULAR FUNCTION
Haemodynamic variables determined at initial
examination have not been associated with
improvement in left ventricular systolic
function.5 7 8 The extent of myocardial fibrosis
in endomyocardial biopsies and the alcohol
intake have been reported to be factors
influencing improvement in left ventricular
systolic function.8 16 In our study, there was no
statistical diVerence between the initial haemo-
dynamic findings and the alcohol intake
between patients with and without improve-
ment, although patients with improvement had
slightly lower baseline left ventricular end
diastolic pressure and pulmonary capillary
wedge pressure and a higher cardiac index than
those without improvement, suggesting better
cardiac function and reserve. Myocardial biop-
sies were not obtained. Thallium scintigraphy
did not reveal any diVerence in uptake score or
prevalence of large perfusion defects between
patients with and without improvement. It is
therefore important to find other means of pre-
dicting improvement in left ventricular systolic
function non-invasively in patients with DCM.
DOBUTAMINE STRESS ECHOCARDIOGRAPHY
Pharmacological stress echocardiography with
dobutamine is recognised as useful in patients
with myocardial infarction. It is reported that
myocardial viability can be identified, using low
dose dobutamine stress, as a functional im-
provement in regions with rest dyssynergy. The
wall motion response during dobutamine infu-
sion is useful in predicting of recovery of
stunned myocardium and hibernating myocar-
dium in patients with ischaemic heart
disease.11 12
However, there are few reports concerning
the significance of dobutamine stress echo-
cardiography in patients with DCM. Vigna et al
reported that the analysis of regional contrac-
tion by dobutamine stress echocardiography
could distinguish between ischaemic and non-
ischaemic left ventricular dysfunction.17 How-
ever, to our knowledge, this is the first report on
predicting the recovery of systolic function by
dobutamine stress echocardiography in patients
with DCM. The exact mechanism of this
recovery is unclear. One explanation is the
degree of downregulation of the myocardial â
adrenergic system, since this has been reported
to be associated with progressive left ventricular
deterioration. Patients with improvement show
the better heart rate response to low dose dob-
utamine as well as to low level exercise, suggest-
ing that contractile reserve related to â adrener-
gic stimulation may be the predominant factor
in the improvement in wall motion score.
Doubois-Rande et al investigated the relation
between the contractile responsiveness to intra-
coronary dobutamine infusion and the clinical
outcome in patients with DCM, and reported
that diminished â adrenergic contractile reserve
was predictive of the clinical outcome.18 There
may also be “non-contractile but viable”
myocardium in patients with non-ischaemic left
ventricular dysfunction, and this may play a
part in the recovery of systolic function.
STUDY LIMITATIONS
Limitations include the small number of
patients studied and the retrospective nature of
the study. Another limitation is the variation in
drug treatment. In particular, patients showing
improvement in LVEF were more likely to be
receiving â blockers, and it has been reported
that â blockers and ACE inhibitors improve
LVEF in diVerent ways. Finally, myocardial
biopsies were not performed, although we
excluded patients clinically suspected of having
myocarditis or secondary myocardial disease.
CLINICAL IMPLICATIONS
Dobutamine stress echocardiography can safely
be applied to patients with DCM and may pre-
dict the extent of recovery of left ventricular
systolic function. The findings of this study may
be useful in the decision making process before
heart transplantation or left ventricular volume
reduction (Batista operation).
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